News and Announcements
Shivom Strikes Strategic Alliance with Genetic Technologies Limited (ASX: GTG)
- Published March 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Genetic Technologies Limited a diversified molecular diagnostics company; provider of BREVAGenplus: registered, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, has announced its plans to collaborate with Project Shivom.
The partnership aims to build on the technologies of GTG Labs and Project Shivom’s reach. Dr Paul Kasian, Genetic Technologies’ Chairman commented: “The Board is excited about the opportunity to collaborate with Project Shivom on its unique blockchain platform. Where the formal terms are agreed with Project Shivom, access to such a large database of genomic data would allow GTG to utilize its SNP based risk assessment technologies.”
To read the full ASX announcement made by GTG please click here.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.